Working… Menu

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00635557
Recruitment Status : Unknown
Verified March 2011 by Myrexis Inc..
Recruitment status was:  Active, not recruiting
First Posted : March 13, 2008
Last Update Posted : March 25, 2011
Information provided by:
Myrexis Inc.

Brief Summary:
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: MPC-6827 + Carboplatin Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dose Finding Phase 1 Study of the Treatment of Recurrent/Relapsed Glioblastoma Multiforme With MPC-6827 in Combination With Carboplatin
Study Start Date : March 2008
Actual Primary Completion Date : October 2010
Estimated Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Carboplatin

Intervention Details:
  • Drug: MPC-6827 + Carboplatin
    MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.

Primary Outcome Measures :
  1. Maximum tolerated dose [ Time Frame: After each cohort is enrolled and all subjects have completed 1 cycle ]

Secondary Outcome Measures :
  1. Pharmacokinetics [ Time Frame: Cycle 1 only ]
  2. Antitumor activity [ Time Frame: Screening, end of each cycle, end of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven WHO Grade IV glioblastoma multiforme at time of diagnosis or relapse
  • Prior treatment with radiotherapy and temozolomide
  • Evidence of measurable recurrent or residual primary tumor by contrast-enhanced MRI
  • Be a minimum of 4 weeks since prior surgical resection, major surgical procedure, radiation therapy or cytotoxic chemotherapy (6 weeks since prior BCNU or CCNU)
  • Have a Performance Scale of Karnofsky > 60%, ECOG < 2 or WHO < 2
  • If steroids are needed, be on a stable or decreasing dose of steroids for at least 1 week

Exclusion Criteria:

  • Hypersensitivity to Cremophor EL
  • Have evidence of current/active intratumor hemorrhage by MRI
  • Have greater than second relapse
  • Have had prior treatment with platinum-based chemotherapy
  • Have cardiovascular disease
  • Have cerebrovascular disease
  • Have uncontrolled hypertension
  • Have a cardiac ejection fraction < 50%
  • Have Troponin-I elevated above the normal range

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00635557

Layout table for location information
United States, California
The Angeles Clinic and Research Institute
Los Angeles, California, United States, 90025
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, New York
Mt. Sinai School of Medicine
New York, New York, United States, 10029
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Myrexis Inc.
Layout table for investigator information
Study Director: Andrew P. Beelen, MD Myrexis Inc.
Layout table for additonal information
Responsible Party: Andrew P. Beelen, MD / Sr. Director of Clinical Research, Myrexis Inc. Identifier: NCT00635557    
Other Study ID Numbers: MPC-6827-07-004
MPC-6827 GBM
First Posted: March 13, 2008    Key Record Dates
Last Update Posted: March 25, 2011
Last Verified: March 2011
Keywords provided by Myrexis Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents